Charles joined the Board of IXICO in 2013. He is an experienced Director of, and adviser to, public and private companies primarily in the medtech and life science sectors. He is Non-Executive Chairman of Realm Therapeutics plc, Creo Medical Group plc and 11 Health Technologies Limited and chairs the UK Department of Health Invention for Innovation Funding Panel.
CHIEF FINANCIAL OFFICER
AND COMPANY SECRETARY
Susan joined IXICO as Chief Financial Officer in October 2014. She is an experienced Executive Director with previous Board positions including Group Chief Financial Officer of Novacyt SA and Chief Financial Officer of Lab21 Ltd prior to its acquisition by Novacyt. Susan was Chief Financial Officer of BioWisdom until its acquisition by Instem plc and Finance Director of RiboTargets Limited until its acquisition by Vernalis plc.
Mark joined the Board of IXICO in 2016. He is Chief Executive Officer of DeepMatter Group plc. Mark is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group plc, a leading intellectual property commercialisation company, where he led the Healthcare team. Mark is a Non-Executive Director of hVIVO plc and Genomics plc.
CHIEF EXECUTIVE OFFICER
Giulio joined IXICO as Chief Executive Officer in February 2017. He has over 30 years of experience in the life sciences sector and a track record of growing business operations in Europe, the US and Asia. Prior to IXICO, Giulio held global leadership roles at ThermoFisher Scientific and the LGC Ltd, where he transformed the scale of LGC’s Genomics division, completing 3 acquisitions in under 18 months. Giulio was a member of the executive leadership responsible for the successful sale of the LGC Ltd to global investment firm, KKR & Co. Inc.
AND SENIOR INDEPENDENT DIRECTOR
Tim has more than 25 years’ experience in the life sciences sector with various pharmaceutical, biotechnology and pharmaceutical service companies in Europe and the US. He has broad experience in drug development, product licensing, mergers, acquisitions and fundraisings. Tim is currently Chief Operating Officer at hVIVO plc. His previous positions include Chief Executive Officer at Phytopharm plc and Serentis Limited and Executive Vice President at Vectura plc. Tim joined the Board of IXICO in 2013 and chairs the Remuneration Committee.
John is a chartered accountant with more than 20 years’ experience as a Chief Financial Officer with venture capital backed and listed companies. He is the Chief Financial Officer of Syncona Investment Management Limited, the Investment Manager of Syncona Limited, a FTSE 250-listed life sciences investment company. He is a non-executive director and Audit Committee Chair of IXICO and AIM listed company Creo Medical Group plc.
To speak to one of our experts and find out more